Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 54 Biliary Tract Neoplasms 23 Nasopharyngeal Carcinoma 22 Carcinoma, Non-Small-Cell Lung 22 Cholangiocarcinoma 21 Urinary Bladder Neoplasms 18 Breast Neoplasms 18 Neoplasm Metastasis 17 Lung Neoplasms 14 Lymphoma, Large B-Cell, Diffuse 13 Colorectal Neoplasms 12 Carcinoma, Transitional Cell 12 Non-Muscle Invasive Bladder Neoplasms 10 Recurrence 8 Ovarian Neoplasms 8 Triple Negative Breast Neoplasms 7 Sarcoma 7 Neoplasms 6 Hodgkin Disease 6 Gallbladder Neoplasms 6 Nasopharyngeal Neoplasms 5 Bile Duct Neoplasms 5 Adenocarcinoma 5 Uterine Cervical Neoplasms 4 Locally Advanced Pancreatic Cancer 4 Endometrial Neoplasms 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Adenocarcinoma 3 Osteosarcoma 3 Lymphoma 3

Interventions

liposomal doxorubicin 3 1-dodecylpyridoxal 2 pembrolizumab 1 mirabegron 1 disitamab vedotin 1 anlotinib 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Ovarian Cancer Recurrent × Gemcitabine × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡